Finanzen von Silexion Therapeutics Corp (SLXN)SLXNSilexion Therapeutics Corp

Evaluating the bottom line, Silexion Therapeutics Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -897.46%, provide a clear picture of how effectively SLXN converts its operational activities into shareholder value.

In the context of the broader market, SLXN competes directly with industry leaders such as SHPH and HELP. With a market capitalization of $2.34M, it holds a significant position in the sector. When comparing efficiency, SLXN's gross margin of N/A stands against SHPH's N/A and HELP's N/A. Such benchmarking helps identify whether Silexion Therapeutics Corp is trading at a premium or discount relative to its financial performance.

Silexion has reported continuous net losses, with the latest net income showing a loss of $2,733,000 in Q1 2026. The company has a current ratio of 1.00, indicating it is just able to cover its short-term liabilities, but its debt to equity ratio is extremely high at 533.68%, reflecting significant financial risk.